1. Introduction {#sec0005}
===============

Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has become a global pandemic.[@bib0195] Its origin remains unclear. Several studies suggested that bats might be the natural host for SARS-CoV-2,[@bib0200], [@bib0205] while snakes and pangolins were potential intermediate hosts of SARS-CoV-2 transmission to humans.[@bib0210], [@bib0215], [@bib0220], [@bib0225], [@bib0230]

Various types of virus hosted in wild animals can threaten human health and safety. The Squama Manitis (pangolin scale) is a medicinal material in traditional Chinese medicine (TCM), commonly used to promote lactation in women and reduce swelling.[@bib0235] Due to the exaggeration of its medicinal value, pangolins were facing extinction caused by excessive killing.[@bib0240] In 2019, pangolin has been listed in the International Union for Conservation of Nature (IUCN) Red List of threatened species. In order to enhance the protection of pangolin, China officially proclaimed pangolin to be a national level protected wildlife animal on June 3, 2020.[@bib0245] In Chinese Pharmacopoeia(2020 edition), Squama Manitis has been removed.

Till now, the clinical value of Squama Manitis has not been well assessed. Whether Squama Manitis has special clinical effect? Whether researchers need to find substitutes? Answers to these questions should be based on clinical evidence. This review aimed to summarize all the clinical studies to generate reliable evidence for decision-making on the medicinal value of Squama Manitis.

2. Methods {#sec0010}
==========

2.1. Search strategy {#sec0015}
--------------------

We developed a comprehensive literature search by electronic literature databases including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure Database (CNKI), WanFang Database and SinoMed from inception to May 1, 2020. "Pangolin", "Squama Manitis", "Manis crassicaudata", "Manis javanica", "Malayan pangolins", "Manis pentadactyla", "Ling Li", "Chuan Shan Jia", "Shan Jia", "Pao Jia Zhu", "Jia Pian" and "Pao Shan Jia" were used as key words in different databases. The search strategy in PubMed is presented in **supplement 1** and the search strategy in CNKI is presented in **supplement 2**.

2.2. Eligibility criteria {#sec0020}
-------------------------

We included all types of clinical studies in this review, consisting of randomized controlled trials (RCTs), case control studies (CCSs), case series and case reports. No restriction was applied on age, gender or ethnicity. For controlled studies, trials that applied Squama Manitis at any dosage for the intervention groups were included, either alone or in combination with herbal or western medicine. Routine treatment used in both intervention and control groups were the same. As for case series and case reports, we only included studies which used Squama Manitis alone. There were no restrictions on the outcomes of included studies.

2.3. Data selection and data extraction {#sec0025}
---------------------------------------

Two reviewers (KW, NL) screened all included studies by titles and abstracts according to the eligibility criteria. Any disagreement in the study selection was resolved by consulting a third reviewer (WZ). Eligible studies were reviewed by two researchers (KW, NL) and data was extracted independently. Data was extracted using a pre-designed excel sheet including authors, years of publication, interventions, diseases and outcomes. After cross-check, any inconformity in data extraction was resolved by discussing or consulting with a third researcher (WZ).

2.4. Assessment of risk of bias {#sec0030}
-------------------------------

The quality of RCTs was assessed by Cochrane Risk of Bias (RoB) assessment tool,[@bib0250] which included six aspects: (1) Random sequence generation, (2) Allocation concealment, (3) Blinding of participants and personnel, (4) Incomplete outcome data, (5) Selective reporting, (6) Other bias. The assessment results were presented as "low risk", "high risk" or "unclear risk". The quality of CCSs was assessed by Newcastle-Ottawa Scale (NOS).[@bib0255] The NOS contained three components with eight questions: (1) selection of the groups of the study, (2) comparability, (3) assessment of the outcome. A scoring system of 9 points was used to assess the quality of CCSs; higher score means better quality. Two researchers carried out the quality assessment independently. Disagreement was resolved after consensus or consulting a third researcher.

2.5. Data analysis {#sec0035}
------------------

Review Manager (RevMan) version 5.3 was used to perform statistical analysis. Risk ratio (RR) with a 95% confidence interval (CI) was adopted for dichotomous outcomes. Mean difference (MD) with a 95% CI was used for continuous outcomes. Cochrane\'s *Q* and *I*^2^ were used to explore the heterogeneity among studies. Due to different diseases, interventions and outcomes reported in the included studies, no meta-analysis was performed to merge data.

3. Results {#sec0040}
==========

A total of 4640 records were identified as potentially eligible for inclusion. After excluding duplicates, 3026 studies were screened by their titles and abstracts. According to the eligibility criteria, 151 articles were preliminarily selected for further assessment and 136 of them were excluded, which were review articles, animal experiments, pharmaceutical researches and theory analysis. Finally, 15 articles were included for analyses ([Fig. 1](#fig0005){ref-type="fig"}).Fig. 1Flow diagram of literature search and trials selection.

3.1. Characteristics of included studies {#sec0045}
----------------------------------------

Types of the 15 included studies[@bib0260], [@bib0265], [@bib0270], [@bib0275], [@bib0280], [@bib0285], [@bib0290], [@bib0295], [@bib0300], [@bib0305], [@bib0310], [@bib0315], [@bib0320], [@bib0325], [@bib0330] were 4 RCTs,[@bib0260], [@bib0265], [@bib0270], [@bib0275] 1 CCS,[@bib0280] 3 case series[@bib0285], [@bib0290], [@bib0295] and 7 case reports.[@bib0300], [@bib0305], [@bib0310], [@bib0315], [@bib0320], [@bib0325], [@bib0330] These studies were published from 1989 to 2018, with 80% of them published 10 years ago. Fifteen studies covered 15 types of diseases, including postpartum hypogalactia, breast hyperplasia, acute mastitis, mesenteric lymphadenitis, leukopenia, prostatic hyperplasia, paronychia, hyperlipidemia, chronic leg ulcer, periarteritis nodosa, verruca plana, neurodermatitis, parkinsonian disorders, glomerulonephritis, periarthritis of the shoulder. Details of RCTs and non-RCTs were shown in [Table 1](#tbl0005){ref-type="table"} and [Table 2](#tbl0010){ref-type="table"} respectively.Table 1Characteristics of the included RCTs.Table 1First author (Year) \[ref\]Study typeSample size (T/C)DiseaseInterventionControlCourse of treatmentFollow-upOutcomeResults RR, 95% CI, *P*-valueLiang (2018)[@bib0260]RCTs243 (123/120)Postpartum hypogalactiaSquama Manitis powder + Cherbal decoctionNot reportedNot reportedEfficacy rate1.21 (1.11,1.32), *P* \< 0.00001Jiang (2007)[@bib0265]RCTs100(50/50)Breast hyperplasiaSquama Manitis powder + CHerbal decoctionNot reportedNot reportedEfficacy rate1.07 (0.96,1.19), *P* = 0.24Zhang (2011)[@bib0270]RCTs96 (48/48)Acute mastitisSquama Manitis powder + CCefuroxime Sodium for Injection5 daysNot reportedEfficacy rate1.13 (0.95,1.35), *P* = 0.16Zhu (2013)[@bib0275]RCTs86 (43/43)Mesenteric lymphadenitisSquama Manitis powder + CCeftriaxone Sodium for Injection10 days30 daysEfficacy rate1.51 (1.09,2.09), *P* = 0.01Table 2Characteristics of the included non-RCTs.Table 2First author (year) \[ref\]Study typeSample size (T/C) conditionsDiseaseInterventionControlTreatment follow-upResultsWang (1994)[@bib0280]CCSs53(13/40)LeukopeniaSquama Manitis powderLeucogen Tablets, Tabellae Batiloli30-60 days not reportedLeucocyte count\
Treatment group: 5 × 10^9^/L--6 × 10^9^/L\
Control: (4-5) × 10^9^/L--5 × 10^9^/LZhang (1997)[@bib0285]Case series42Prostatic hyperplasiaSquama Manitis powderNone14-28 days\
6 months to 4 yearsEfficacy rate: 95%Li (2004)[@bib0290]Case series100ParonychiaSquama Manitis powder (topical usage) + Conventional disinfectionNone7 days not reportedEfficacy rate: 100%Fan (2002)[@bib0295]Case series62HyperlipidemiaSquama Manitis powderNone60 days not reportedEfficacy rate lowering cholesterol: 74%; lowering triglyceride: 65.5%Qian (1989)[@bib0300]Case report5Chronic leg ulcerSquama Manitis powder (topical usage)None12 days not reportedThe ulcer healed without scars or pigmentationLi (1991)[@bib0305]Case report1Periarteritis nodosaSquama Manitis powderNone31 days\
5 yearsSwelling and pain in periartheritis nodosa relieved, nodules disappeared and the disease recoveryWu (2000)[@bib0310]Case report1Verruca planaSquama Manitis powderNone5 days\
20 daysVerruca plana healed without scarringPan (2001)[@bib0315]Case report1NeurodermatitisSquama Manitis Quicklime Water Infusion (topical usage)None4 days\
30 daysThe itching disappeared and the skin returned to normal after 1 monthJin (2002)[@bib0320]Case report1Parkinsonian disordersSquama Manitis powderNone90 days\
2 yearsAfter 3 months, the tremors of the upper and lower lips stopped, and there was no recurrence after 2 years of follow-upTian (2002)[@bib0325]Case report1GlomerulonephritisSquama Manitis powderNone6 days\
not reportedUrine colour was light yellow after 1 week and routine urine test result returned to normalRen (2005)[@bib0330]Case report1Periarthritis of the shoulderSquama Manitis powderNone30 days\
3 yearsShoulder pain were significantly alleviated after 1 week, and healed after 1 month without recurrence for 3 years

3.2. Risk of bias {#sec0050}
-----------------

The risk of bias assessment on each included RCT was presented in [Fig. 2](#fig0010){ref-type="fig"}, [Fig. 3](#fig0015){ref-type="fig"}. Among the included RCTs, two were assessed with a high risk of selection bias due to their incorrect utilization of randomization methods.[@bib0260], [@bib0265] The other two RCTs did not clearly report how to generate random sequence. One RCT of Squama Manitis in the treatment of postpartum hypogalactia was assessed with a high risk of selection bias due to its incorrect usage of allocation concealment methods[@bib0260] and the remaining RCTs had unclear allocation concealment. There was also a lack of clear report in blinding of participants and personnel and blinding of outcomes assessment, resulting in an unclear assessment for performance and detection bias. High attrition bias was assessed for one RCT using Squama Manitis in the treatment of mesenteric lymphadenitis in children, with a loss of 4 patients in the control group during follow up.[@bib0275] The other 3 RCTs were assessed with a low risk of attribution bias. Reporting bias for all included RCTs was assessed unclear due to the lack of pre-registered study protocols.Fig. 2Risk of bias graph.Fig. 3Risk of bias summary. +: low risk of bias; −: high risk of bias; ?: unclear risk of bias.

One CCS\'s quality was assessed by NOS.[@bib0280] Though the study reported the selection of controls (both groups of patients were from the same hospital and the same department), the rest items of NOS were lack of clarity, hence the study was scored as 1 point.

3.3. Clinical efficacy {#sec0055}
----------------------

The results of the 4 RCTs were described as follows. Liang (2018) tested the efficacy rate of Squama Manitis for treating postpartum hypogalactia.[@bib0260] They randomly allocated 243 patients treated with either Squama Manitis powder combined with herbal decoction (*n* = 123) or herbal decoction alone (*n* = 120). The results showed that Squama Manitis powder combined with herbal decoction has a higher efficacy rate than using herbal decoction alone (RR 1.21, 95% CI 1.11--1.32, *P* \< 0.00001).

Jiang (2007) tested the efficacy rate of Squama Manitis for treating breast hyperplasia.[@bib0265] They randomly allocated 100 patients into Squama Manitis powder combined with herbal decoction (*n* = 50) and herbal decoction (*n* = 50). The result showed no statistical difference in efficacy rate between the two groups (RR 1.07, 95% CI 0.96--1.19, *P* = 0.24).

Zhang (2011) tested the efficacy rate of Squama Manitis for treating acute mastitis.[@bib0270] They randomly allocated 96 patients into Squama Manitis powder combined with Cefuroxime Sodium for Injection (*n* = 48) and Cefuroxime Sodium for Injection (*n* = 48). The result was inconclusive because there was no statistical significant difference between the two groups (RR 1.13, 95% CI 0.95--1.35, *P* = 0.16).

Zhu (2013) tested the efficacy rate of Squama Manitis for treating mesenteric lymphadenitis.[@bib0275] They randomly allocated 86 patients into Squama Manitis powder combined with Ceftriaxone Sodium for Injection (*n* = 43) and Ceftriaxone Sodium for Injection (*n* = 43). The result showed that the effect of Squama Manitis powder combined with Ceftriaxone Sodium for Injection was better than Ceftriaxone Sodium for Injection alone (RR 1.51, 95% CI 1.09--2.09, *P* = 0.01).

The CCS recruited 13 patients in Squama Manitis group and 40 patients in control group.[@bib0280] Number of leukocytes in both groups before and after treatment were reported. The total number of leukocytes in the treatment group was maintained at about 6 × 10^9^/L, and that in the control group was maintained at 5 × 10^9^/L.

There were 3 case series[@bib0285], [@bib0290], [@bib0295] about prostatic hyperplasia, paronychia and, hyperlipidemia, with the sample size of 42, 100 and 62 respectively. According to the results, the effeicacy rate of Squama Manitis powder for prostatic hyperplasia was 95%.[@bib0285] Squama Manitis powder (topical usage) combined with conventional disinfection had 100% efficacy rate for treating paronychia.[@bib0290] The efficacy rate of Squama Manitis powder were 74% and 65.5% respectively for lowering cholesterol and triglyceride.[@bib0295]

There were 7 case reports,[@bib0260], [@bib0265], [@bib0270], [@bib0275], [@bib0280], [@bib0285], [@bib0290] which covered diseases of chronic leg ulcer, periarteritis nodosa, verruca plana, neurodermatitis, parkinsonian disorders, glomerulonephritis and periarthritis of the shoulder. The results of these case reports showed that Squama Manitis had effect on above diseases. However, these case reports and case series could not provide any relaible evidence for the efficacy of Squama Manitis.

4. Discussion {#sec0060}
=============

This review evaluated the current clinical evidence of Squama Manitis. There were 4 RCTs, 1 CCS, 3 case series and 7 case reports included in this review. The results of RCTs suggested that Squama Manitis combined with herbal decoction or antibiotics could bring additional benifit for treating postpartum hypogalactia and mesenteric lymphadenitis. While for breast hyperplasia and acute mastitis, the results were inconclusive. Results from non-RCTs showed that Squama Manitis might be effective in treating leukopenia, prostatic hyperplasia, paronychia, hyperlipidemia, chronic leg ulcer, periarteritis nodosa, verruca plana, neurodermatitis, parkinsonian disorders, glomerulonephritis and periarthritis of the shoulder. Most of the diseases mentioned above have conventional effective treatments. It is deemed unnecessary to use Squama Manitis.

Further more, results from above studies should be interpreted with caution due to low methodological quality which would lead to significant biases. The 4 RCTs included in this review have small sample sizes, and focused on different diseases. As a consequence, no meta-analysis was performed to generate powerful results. Moreover, there was a lack of rational and valuable outcome measures in the included studies. And the reporting quality of included case reports was low due to the incompleteness in the records of diagnosis and treatment and unstandardization in the outcomes measurement for efficacy. Furthermore, case reports without control could not test the efficacy of Squama Manitis. In general, all the non-RCTs did not add any valuable evidence to the efficacy of Squama Manitis.

There were also several limitations in this review. A protocol was not registered or published before conducting this systematic review. Although a comprehensive literature search was performed in commonly used databases, there was also potential omission of grey literatures due to the lack of alternative search methods. Clinical studies using Squama Manitis or combined with other drugs were reviewed, while clinical studies using TCM prescriptions containing Squama Manitis were not included in this review. Hence, it was impossible to evaluate the efficacy of Squama Manitis in TCM prescriptions in this review.

Based on above data-analyse, there was no reliable evidence for the clinical value of Squama Manitis. Furthermore, there might be a risk of experiencing anaphylaxis in the consumption of Squama Manitis. Several studies reported that the use of Squama Manitis might trigger allergic reactions such as dizziness, chills, shortness of breath, sweating, pruritus, skin redness and rashes.[@bib0335], [@bib0340], [@bib0345] Pangolin is one kind of wildlife on the verge of extinction. There is no reason to use Squama Manitis in clinical practice.

Wild pangolins may carry pathogens that can cause infections in human beings.[@bib0220] Hence, it is highly recommended to restrict the use of Squama Manitis as medicine or food in order to protect endangered wildlife species and human safety.[@bib0350] In the recent edition of the Chinese Pharmacopoeia, Squama Manitis has been removed out.

There are still several Chinese patent medicines containing Squama Manitis listed in the Chinese Pharmacopoeia (2015 edition), such as compound Tongbi capsule, Guilingji, Huixiangjuhe pill, Kangsuan (antithrombotic) Zaizao pill, Tongru granule and Jinpu capsule being used clinically. Therefore, it is necessary to carry out studies on substitutes for these medicines. Several studies have shown that there are similarities in the composition of pig\'s hoof nails and Squama Manitis in regards to the trace elements and inorganic contents through thin layer, column and spectrum chromatography analysis.[@bib0355], [@bib0360], [@bib0365], [@bib0370], [@bib0375], [@bib0380]

In conclusion, there is no reliable evidence for the clinical value of Squama Manitis. It is rational to prohibit the use of Squama Manitis for treatment or healthcare purpose.
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